Bristol Myers, Cancer Drug
Bristol Myers Squibb (NYSE:BMY) has received a recommendation for approval from the Committee for Medicinal Products for ...
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
2 Beaten-Down Dividend Stocks to Buy and Hold was originally published by The Motley Fool Despite soft inflation print, bond ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other dividend contenders. Dividend stocks have long been favored by investors ...
Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to ...
Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (WBAG:BMYS) from Market Perform to Outperform. There are 3,419 funds or institutions ...
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...